Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Danish pharma company Novo Nordisk has announced an agreement to acquire drug delivery specialist Emisphere Technologies for $1.8bn.
Novo is set to acquire all outstanding shares in Emisphere for $1.35bn and will also purchase related Eligen SNAC royalty stream obligations owed to MHR Fund Management for $450m.
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide).
Eligen SNAC is a drug delivery platform that uses synthetic chemical compounds – known as Emisphere delivery agents – to allow small and large molecule drugs to be taken orally without their chemical form being altered by processes in the body.
Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists.
Read more: http://www.pmlive.com/pharma_news/novo_nordisk_set_to_acquire_emisphere_technology_for_$1.8bn_1356399
Novo is set to acquire all outstanding shares in Emisphere for $1.35bn and will also purchase related Eligen SNAC royalty stream obligations owed to MHR Fund Management for $450m.
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide).
Eligen SNAC is a drug delivery platform that uses synthetic chemical compounds – known as Emisphere delivery agents – to allow small and large molecule drugs to be taken orally without their chemical form being altered by processes in the body.
Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists.
Read more: http://www.pmlive.com/pharma_news/novo_nordisk_set_to_acquire_emisphere_technology_for_$1.8bn_1356399
